|
| Human CD84/SLAMF5 Protein (LTP10575) |
|
| LTP10575 |
|
| 100ug |
|
|
$305 In stock |
| Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD5 B lymphocytes in peripheral blood, lymphoid organs and bone marrow. The main feature of the disease is accumulation of the malignant cells due to decreased apoptosis. CD84 belongs to the signaling lymphocyte activating molecule family of immunoreceptors, and has an unknown function in CLL cells. |
| Recombinant Human CD84/SLAMF5 Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal. It contains Lys22-Gly225. |
|
| CD84/SLAMF5 |
|
| Human |
|
| Q9UIB8-1 |
|
| Lys22-Gly225 |
|
| The protein has a predicted MW of 25.4 kDa. Due to glycosylation, the protein migrates to 40-55 kDa based on the Tris-Bis PAGE result. |
|
| 0 |
|
| C-His-Avi |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
